Specialised Therapeutics Asia Pte Ltd (ST), an independent biopharmaceutical company, is embarking on a strategic partnership with Treeway BV, a biotechnology firm based in the Netherlands. The collaboration aims to bring forth a new therapeutic option for Amyotrophic Lateral Sclerosis (ALS), the most prevalent form of Motor Neurone Disease (MND), to patients in Australia and New Zealand.

This innovative therapy, designated as TW001, represents a novel oral formulation of edaravone, targeting the reduction of oxidative damage linked to neuron degeneration in ALS. The treatment, currently under evaluation in the pivotal ADORE phase III registration study spanning nearly 40 global locations, holds significant promise for enhancing patient care.

According to Australian neurologist Associate Professor Susan Mathers, approximately 2000 individuals are living with MND at any given time in Australia. The advent of an oral therapy like edaravone offers a notable advantage, enabling patients to manage their condition from the comfort of their homes. Associate Professor Mathers remarked, "There is a pressing need for improved disease-modifying therapies that can potentially slow or even halt the progression of this condition. Oral therapies like edaravone provide a simple yet effective option that patients can self-administer at home, supervised by their local healthcare providers."

Key patient advocacy organization MND Australia also expressed its enthusiasm for the potential benefits of this new oral treatment. Gethin Thomas, Executive Director of Research, highlighted that oral edaravone would complement the recently approved intravenous edaravone in Australia, widening the pool of patients who can access treatment.

Per the terms of the licensing agreement, ST will take charge of marketing, regulatory affairs, and distribution activities concerning TW001 for ALS/MND in the Australian and New Zealand regions.

ST's Chief Executive Officer, Carlo Montagner, hailed TW001 as the first central nervous system (CNS) therapy to join the company's therapeutic portfolio. He emphasized the alignment of this collaboration with ST's regional expertise and commitment to providing unique therapeutic solutions to the region that might otherwise remain unavailable.

Montagner stated, "We are excited to join forces with Treeway as we witness the promising progress of this treatment through the final stages of the pivotal global registration ADORE study. We eagerly anticipate collaborating with the broader MND community, which is dedicated to accessing novel therapies for this devastating disease. While a definitive cure for MND is still elusive, our optimism remains high that treatments like TW001 could potentially slow disease progression and enhance patient outcomes."

Treeway CEO Inez de Greef echoed this sentiment, emphasizing the therapy's favorable results in previous studies. De Greef expressed eagerness for further findings from the ADORE study and subsequent collaboration with ST to ensure the availability of the therapy to all eligible patients in Australia and New Zealand. De Greef highlighted that ST's commitment to introducing new therapies to the market for conditions with unmet medical needs aligns seamlessly with Treeway's vision for a licensing partnership.

 

Source: prnewswire.com

Report Abuse